Quan Anh Vu Buys 1,500 Shares of Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) CFO Quan Anh Vu acquired 1,500 shares of the company’s stock in a transaction dated Friday, December 26th. The shares were bought at an average cost of $69.95 per share, with a total value of $104,925.00. Following the completion of the acquisition, the chief financial officer directly owned 1,500 shares in the company, valued at $104,925. The trade was a ? increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Monopar Therapeutics Stock Down 0.8%

MNPR opened at $65.07 on Wednesday. The business’s fifty day simple moving average is $78.99 and its 200 day simple moving average is $60.71. Monopar Therapeutics Inc. has a 52 week low of $21.00 and a 52 week high of $105.00. The stock has a market cap of $434.86 million, a PE ratio of -18.92 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). As a group, equities analysts anticipate that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Institutional Trading of Monopar Therapeutics

Several large investors have recently modified their holdings of the business. AlphaQuest LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $44,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Monopar Therapeutics in the 1st quarter worth approximately $328,000. Goldman Sachs Group Inc. purchased a new position in shares of Monopar Therapeutics during the first quarter valued at approximately $673,000. Jane Street Group LLC purchased a new position in shares of Monopar Therapeutics during the first quarter valued at approximately $377,000. Finally, Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after acquiring an additional 48,379 shares in the last quarter. 1.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MNPR has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, September 24th. HC Wainwright set a $105.00 target price on shares of Monopar Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 29th. BTIG Research upped their price target on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Piper Sandler set a $95.00 price objective on Monopar Therapeutics and gave the company an “overweight” rating in a research note on Thursday, September 25th. Finally, Lake Street Capital started coverage on Monopar Therapeutics in a report on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Monopar Therapeutics has a consensus rating of “Buy” and an average target price of $106.20.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.